{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-240603","form_type":"8-K","ticker":"IKT","cik":"0001750149","company_name":"Inhibikase Therapeutics, Inc.","filed_at":"2024-10-22T23:59:59+00:00","discovered_at":"2026-05-14T18:03:09.460522+00:00","generated_at":"2026-05-30T11:42:44.571734+00:00","sec_items":["1.01","5.02","7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Inhibikase closes $110M private placement, up to $275M total, advances IkT-001Pro in PAH","bullets":["Gross proceeds ~$110M from private placement; potential aggregate up to ~$275M from warrant exercises.","Proceeds to fund Phase 2b '702' trial of IkT-001Pro in PAH and for general corporate purposes.","Appointed four new directors: Roberto Bellini (Independent Chair), Amit Munshi, David Canner, Arvind Kush.","Resignations of Dr. Paul Grint and Gisele Dion, not due to disagreements; fully vested options paid through Dec 31, 2024.","IkT-001Pro is oral, potentially disease-modifying imatinib prodrug aiming to improve safety/tolerability in PAH."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-240603","json":"https://secwatch.observer/filing/0001193125-24-240603.json","markdown":"https://secwatch.observer/filing/0001193125-24-240603.md","text":"https://secwatch.observer/filing/0001193125-24-240603.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/d902445d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T11:42:44.571734+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"160af5a8bb","claim":"Roberto Bellini was appointed as Class I director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"the Board appointed Roberto Bellini to serve as a Class I director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class I director"}],"fact_type":"executive_change"},{"claim_id":"1a0ce9b5d9","claim":"Roberto Bellini was elected as Independent Chairperson of the Board at Inhibikase Therapeutics, Inc..","evidence_excerpt":"The Board has elected Mr. Bellini as independent Chairperson of the Board.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Independent Chairperson of the Board"}],"fact_type":"executive_change"},{"claim_id":"4249e0c4b6","claim":"Arvind Kush was appointed as Class III director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Arvind Kush to serve as a Class III director of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class III director"}],"fact_type":"executive_change"},{"claim_id":"9d7f2b9f57","claim":"Paul Grint resigned as director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Dr. Paul Grint and Ms. Gisele Dion (the \" Resigning Directors \") became effective as of the effectiveness of the appointment of their respective successors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"ccacd6d34c","claim":"David Canner was appointed as Class II director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Amit Munshi and David Canner to serve as Class II directors of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"},{"claim_id":"e4bca51f57","claim":"Gisele Dion resigned as director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Dr. Paul Grint and Ms. Gisele Dion (the \" Resigning Directors \") became effective as of the effectiveness of the appointment of their respective successors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"director"}],"fact_type":"executive_change"},{"claim_id":"fcf5328ed6","claim":"Amit Munshi was appointed as Class II director at Inhibikase Therapeutics, Inc..","evidence_excerpt":"Amit Munshi and David Canner to serve as Class II directors of the Board","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1750149/000119312524240603/0001193125-24-240603-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Class II director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}